Effects of Antipsychotic Treatment on Tardive Dyskinesia: A 6-Month Evaluation of Patients From the European Schizophrenia Outpatient Health Outcomes (SOHO) Study
J Clin Psychiatry 2005;66(9):1130-1133
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: To compare the incidence and
persistence of tardive dyskinesia between patients diagnosed with schizophrenia (ICD-10
and/or DSM-IV) who were treated with second-generation antipsychotics and first-generation
antipsychotics in routine clinical practice.
Method: The European Schizophrenia
Outpatient Health Outcomes (SOHO) study is a
3-year, prospective, observational study. Each
country had a start date for patient enrollment before
October 2000. All enrollment was completed by June 30, 2001. A simple, global measure of
tardive dyskinesia was rated by participating
clinicians. For the current analysis, data at baseline,
3 months, and 6 months were analyzed using a generalized estimating equation model.
antipsychotics conferred a lower risk for tardive dyskinesia at
6 months than first-generation antipsychotics
(0.9% vs. 3.8%, odds ratio [OR] = 0.29, 95%
confidence interval [CI] = 0.18 to 0.46). In addition,
patients with tardive dyskinesia at baseline who were
receiving second-generation antipsychotics were less likely than patients receiving
first-generation antipsychotics to have tardive dyskinesia
symptoms at 6 months (43.6% vs. 60.8%, OR = 0.50, 95% CI = 0.30 to 0.85). A sensitivity
analysis suggested no bias related to pharmaceutical
industry financial support.
Conclusion: The results suggest that the
relative advantage of second-generation antipsychotics in terms of lower rates of incidence
and persistence of tardive dyskinesia, observed in technical randomized controlled trials,
generalizes to routine clinical care.